{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:16:35Z","timestamp":1770488195810,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40261-016-0466-z","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T07:31:51Z","timestamp":1475825511000},"page":"969-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hydrocodone Bitartrate ER (Hysingla\u00ae ER): A Review in Chronic Pain"],"prefix":"10.1007","volume":"36","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"issue":"6","key":"466_CR1","first-page":"24","volume":"78","author":"TP Jackson","year":"2014","unstructured":"Jackson TP, Stabile VS, McQueen KAK. The global burden of chronic pain. ASA Newsl. 2014;78(6):24\u20137.","journal-title":"ASA Newsl"},{"key":"466_CR2","unstructured":"United Nations Office on Drugs and Crime. Ensuring availability of controlled medications for the relief of pain and preventing diversion and abuse. 2011. https:\/\/www.unodc.org\/docs\/treatment\/Pain\/Ensuring_availability_of_controlled_medications_FINAL_15_March_CND_version.pdf . Accessed 5 Sep 2016."},{"key":"466_CR3","unstructured":"American Academy of Pain Medicine. Use of opioids for the treatment of chronic pain. 2013. http:\/\/www.painmed.org\/files\/use-of-opioids-for-the-treatment-of-chronic-pain.pdf . Accessed 5 Sep 2016."},{"issue":"1","key":"466_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","volume":"65","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. MMWR Recomm Rep. 2016;65(1):1\u201349.","journal-title":"MMWR Recomm Rep"},{"issue":"13","key":"466_CR5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, McLellan AT. Opioid abuse in chronic pain: misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253\u201363.","journal-title":"N Engl J Med"},{"key":"466_CR6","unstructured":"Centers for Disease Control and Prevention. Prescription opioid overdose data. 2016. http:\/\/www.cdc.gov\/drugoverdose\/data\/overdose.html . Accessed 5 Sep 2016."},{"key":"466_CR7","unstructured":"Substance Abuse and Mental Health Services Administration. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. 2013. http:\/\/archive.samhsa.gov\/data\/2k13\/DAWN127\/sr127-DAWN-highlights.htm . Accessed 5 Sep 2016."},{"key":"466_CR8","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2015-0005","author":"ME Hale","year":"2016","unstructured":"Hale ME, Moe D, Bond M, et al. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016. doi: 10.2217\/pmt-2015-0005 .","journal-title":"Pain Manag"},{"key":"466_CR9","unstructured":"Purdue Pharma LP. Purdue Pharma L.P. receives FDA approval for Hysingla\u00ae ER (hydrocodone bitartrate) extended-release tablets CII, a once-daily opioid analgesic formulated with abuse-deterrent properties [media release]. 20 Nov 2014. http:\/\/www.purduepharma.com\/news-media\/2014\/11\/purdue-pharma-l-p-receives-fda-approval-for-hysinglatm-er-hydrocodone-bitartrate-extended-release-tablets-cii-a-once-daily-opioid-analgesic-formulated-with-abuse-deterrent-properties\/ ."},{"key":"466_CR10","unstructured":"Purdue Pharma L.P. Hysingla ER (hydrocodone bitartrate tablet, extended release): US prescribing information. 2015. http:\/\/app.purduepharma.com\/xmlpublishing\/pi.aspx?id=h . Accessed 26 Jul 2016."},{"issue":"1","key":"466_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","volume":"6","author":"H Pathan","year":"2012","unstructured":"Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11\u20136.","journal-title":"Br J Pain"},{"issue":"2","key":"466_CR12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clinthera.2015.12.003","volume":"38","author":"RP Kapil","year":"2016","unstructured":"Kapil RP, Cipriano A, Wen W, et al. Pharmacokinetic profile and sustained 24-hour analgesia of a once-daily hydrocodone bitartrate extended-release tablet with abuse-deterrent properties. Clin Ther. 2016;38(2):302\u201314.","journal-title":"Clin Ther"},{"key":"466_CR13","unstructured":"US FDA Center for Drug Evaluation and Research. Hysingla ER (hydrocodone bitartrate extended-release): clinical pharmacology and biopharmaceutics review(s). 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206627Orig1s000ClinPharmR.pdf . Accessed 5 Sep 2016."},{"issue":"12","key":"466_CR14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/AJP.0000000000000214","volume":"31","author":"OA Linares","year":"2015","unstructured":"Linares OA, Fudin J, Daly AL, et al. Individualized hydrocodone therapy based on phenotype, pharmacogenetics, and pharmacokinetic dosing. Clin J Pain. 2015;31(12):1026\u201335.","journal-title":"Clin J Pain"},{"issue":"10","key":"466_CR15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.clinthera.2015.08.007","volume":"37","author":"RP Kapil","year":"2015","unstructured":"Kapil RP, Friedman K, Cipriano A, et al. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Clin Ther. 2015;37(10):2286\u201396.","journal-title":"Clin Ther"},{"key":"466_CR16","unstructured":"US FDA. Abuse-deterrent opioids-evaluation and labeling: guidance for industry. 2015. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm334743.pdf . Accessed 5 Sep 2016."},{"issue":"Suppl 1","key":"466_CR17","first-page":"S57","volume":"127","author":"A Cipriano","year":"2015","unstructured":"Cipriano A, Giordano J, Das S, et al. In vitro and in vivo evaluation of, and FDA approved labeling for, the abuse-deterrent properties of Hysingla\u00ae ER, a once-daily, single-entity, hydrocodone bitartrate formulation [abstract no. 71 plus poster]. Postgrad Med. 2015;127(Suppl 1):S57.","journal-title":"Postgrad Med"},{"key":"466_CR18","unstructured":"US FDA Center for Drug Evaluation and Research. Hysingla ER (hydrocodone bitartrate extended-release): medical review(s) 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206627Orig1s000MedR.pdf . Accessed 5 Sep 2016."},{"issue":"5","key":"466_CR19","first-page":"820","volume":"17","author":"SC Harris","year":"2015","unstructured":"Harris SC, Cipriano A, Colucci SV, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2015;17(5):820\u201331.","journal-title":"Pain Med."},{"key":"466_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw208","author":"SC Harris","year":"2016","unstructured":"Harris SC, Cipriano A, Colucci SV, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydocodone in recreational users. Pain Med. 2016. doi: 10.1093\/pm\/pnw208 .","journal-title":"Pain Med"},{"issue":"11","key":"466_CR21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1517\/14656566.2015.1060221","volume":"16","author":"W Wen","year":"2015","unstructured":"Wen W, Sitar S, Lynch SY, et al. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Expert Opin Pharmacother. 2015;16(11):1593\u2013606.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"466_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5055\/jom.2015.0283","volume":"11","author":"W Wen","year":"2015","unstructured":"Wen W, Taber L, Lynch SY, et al. 12-month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain. J Opioid Manag. 2015;11(4):339\u201356.","journal-title":"J Opioid Manag"},{"issue":"1","key":"466_CR23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00325481.2016.1134022","volume":"128","author":"L Taber","year":"2016","unstructured":"Taber L, Lynch SY, He E, et al. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Postgrad Med. 2016;128(1):23\u201333.","journal-title":"Postgrad Med"},{"issue":"2","key":"466_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149\u201358.","journal-title":"Pain"},{"issue":"1","key":"466_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2015.993573","volume":"127","author":"A Bartoli","year":"2015","unstructured":"Bartoli A, Michna E, He E, et al. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone\/acetaminophen combination therapy for chronic pain. Postgrad Med. 2015;127(1):5\u201312.","journal-title":"Postgrad Med"},{"issue":"6","key":"466_CR26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5055\/jom.2015.0305","volume":"11","author":"A Bartoli","year":"2015","unstructured":"Bartoli A, Michna E, He E, et al. Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets. J Opioid Manag. 2015;11(6):519\u201333.","journal-title":"J Opioid Manag"},{"key":"466_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12462","author":"K Broglio","year":"2016","unstructured":"Broglio K, Pergolizzi J, Kowalski M, et al. Efficacy and safety of once-daily extended-release (ER) hydrocodone in individuals previously receiving ER morphine for chronic pain. Pain Pract. 2016. doi: 10.1111\/papr.12462 .","journal-title":"Pain Pract"},{"key":"466_CR28","doi-asserted-by":"crossref","unstructured":"Kowalski M, Broglio K, Nalamachu S, et al. Safety and effectiveness of once-daily hydrocodone (Hysingla\u00ae ER) in patients switching from twice-daily oxycodone (OxyContin\u00ae) [abstract no. 14 plus poster]. In: American Society for Pain Management Nursing. 2015.","DOI":"10.1016\/j.jpain.2015.01.367"},{"issue":"Suppl 1","key":"466_CR29","first-page":"S48","volume":"127","author":"K Broglio","year":"2015","unstructured":"Broglio K, Pergolizzi J, Kowalski M, et al. Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients \u226575 years of age with moderate to severe nonmalignant and nonneuropathic pain [abstract no. 60 plus poster]. Postgrad Med. 2015;127(Suppl 1):S48.","journal-title":"Postgrad Med"},{"key":"466_CR30","unstructured":"Campbell K, Kutz JW, Shoup A, et al. No hearing impairment from once-daily, single-entity hydrocodone treatment (Hysingla ER): results of 2 phase-3 studies [abstract no. 149 plus poster]. In: PAINWeek. 2014."},{"key":"466_CR31","unstructured":"US FDA. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use [media release]. 31 August 2016. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm518697.htm ."},{"issue":"2","key":"466_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anclin.2016.01.002","volume":"34","author":"LR Webster","year":"2016","unstructured":"Webster LR. Chronic pain and the opioid conundrum. Anesthesiol Clin. 2016;34(2):341\u201355.","journal-title":"Anesthesiol Clin"},{"issue":"14","key":"466_CR33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.0000000000000839","volume":"83","author":"GM Franklin","year":"2014","unstructured":"Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014;83(14):1277\u201384.","journal-title":"Neurology"},{"key":"466_CR34","unstructured":"NCCN. Adult cancer pain (NCCN guidelines version 2.2016). 2016. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pain.pdf . Accessed 5 Sep 2016."},{"key":"466_CR35","first-page":"CD006605","volume":"1","author":"M Noble","year":"2010","unstructured":"Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"466_CR36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/jamainternmed.2016.1251","volume":"176","author":"C Abdel Shaheed","year":"2016","unstructured":"Abdel Shaheed C, Maher CG, Williams KA, et al. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(7):958\u201368.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"466_CR37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1526-4637.2010.00811.x","volume":"11","author":"E Michna","year":"2010","unstructured":"Michna E, Duh MS, Korves C, et al. Removal of opioid\/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med. 2010;11(3):369\u201378.","journal-title":"Pain Med"},{"issue":"3","key":"466_CR38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","volume":"146","author":"RH Dworkin","year":"2009","unstructured":"Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146(3):238\u201344.","journal-title":"Pain"},{"issue":"9","key":"466_CR39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.pain.2014.05.025","volume":"155","author":"JS Gewandter","year":"2014","unstructured":"Gewandter JS, Dworkin RH, Turk DC, et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain. 2014;155(9):1683\u201395.","journal-title":"Pain"},{"issue":"1","key":"466_CR40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aet126","volume":"111","author":"RA Moore","year":"2013","unstructured":"Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. Br J Anaesth. 2013;111(1):38\u201345.","journal-title":"Br J Anaesth"},{"issue":"2","key":"466_CR41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","volume":"10","author":"R Chou","year":"2009","unstructured":"Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113\u201330.","journal-title":"J Pain"},{"key":"466_CR42","unstructured":"Pernix Therapeutics L. Zohydro\u00ae ER (hydrocodone bitartrate) extended-release capsules: US prescribing information. 2016. http:\/\/www.zohydroer.com\/downloads\/ZOHYDROERFullPrescribingInformation.pdf . Accessed 5 Sep 2016."},{"issue":"4","key":"466_CR43","doi-asserted-by":"crossref","first-page":"E437","DOI":"10.36076\/ppj.2014\/17\/E437","volume":"17","author":"L Manchikanti","year":"2014","unstructured":"Manchikanti L, Atluri S, Candido KD, et al. Zohydro approval by Food and Drug Administration: controversial or frightening? Pain Physician. 2014;17(4):E437\u201350.","journal-title":"Pain Physician"},{"key":"466_CR44","doi-asserted-by":"crossref","unstructured":"Zoginex. Zogenix receives FDA approval of new formulation of Zohydro\u00ae ER [media release]. 30 Jan 2015. http:\/\/ir.zogenix.com\/phoenix.zhtml?c=220862&p=irol-newsArticle_print&ID=2012326 .","DOI":"10.1097\/01.TPM.0000463105.55690.f2"},{"key":"466_CR45","unstructured":"Pernix Therapeutics Holdings Inc. Pernix Therapeutics closes aquisition of Zohydro\u00ae ER franchise [media release]. 24 April 2015. http:\/\/ir.pernixtx.com\/phoenix.zhtml?c=84041&p=irol-newsArticle&ID=2123163 ."},{"issue":"4","key":"466_CR46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","volume":"14","author":"SF Butler","year":"2013","unstructured":"Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351\u20138.","journal-title":"J Pain"},{"issue":"10","key":"466_CR47","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jpain.2013.04.011","volume":"14","author":"SG Severtson","year":"2013","unstructured":"Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122\u201330.","journal-title":"J Pain."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0466-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0466-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0466-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T22:09:08Z","timestamp":1657404548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0466-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,7]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0466-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,7]]}}}